Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
58 hedge funds and large institutions have $170M invested in Alpine Immune Sciences Inc in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 6 closing their positions.
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
4% more funds holding
Funds holding: 56 → 58 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
24% less capital invested
Capital invested by funds: $222M → $170M (-$52.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$4.64M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$4.23M |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$3.81M |
| 4 |
BlackRock
New York
|
+$1.34M |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$10.3M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$3.93M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$2.71M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$1.8M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.24M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Barclays
London,
United Kingdom
| $7K | -$9.51K | -1,103 | -58% |
|
|
AIP
52
Ameritas Investment Partners
Lincoln,
Nebraska
| $7K | – | – | – |
|
53
Simplex Trading
Chicago,
Illinois
| $3K | +$3.41K | +396 | New |
|
54
Wells Fargo
San Francisco,
California
| $2K | -$46.7K | -5,413 | -95% |
|
55
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$5.39K | -625 | -88% |
|
56
Fidelity Investments
Boston,
Massachusetts
| $1K | -$1.14K | -132 | -50% |
|
57
Daiwa Securities Group
Tokyo,
Japan
| $1K | – | – | – |
|
|
58
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$1.24M | -138,279 | Closed |
|
|
TM
59
Tiger Management
New York
| – | -$1.24M | -137,728 | Closed |
|
60
Ensign Peak Advisors
Salt Lake City,
Utah
| – | -$987K | -110,017 | Closed |
|
61
Walleye Capital
New York
| – | -$374K | -41,746 | Closed |
|
|
AA
62
ALPS Advisors
Denver,
Colorado
| – | -$269K | -30,030 | Closed |
|
|
KCIA
63
Kingsbury Capital Investment Advisors
Wilmette,
Illinois
| – | -$262K | -29,153 | Closed |
|
|
CS
64
Credit Suisse
Zurich,
Switzerland
| – | +$129 | +15 | New |
|
ALPN Hedge Fund Activity: Q2 2022 in Review
58 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q2 2022, worth a combined $170M — down 24% from $222M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ALPN positions and 6 closed out — a net gain of 3 holders — while 22 added to existing stakes and 17 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $4.64M. The largest seller was Frazier Life Sciences Management, cutting an estimated $10.3M.
- 58 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q2 2022, up from 56 in Q1 2022.
- Funds reported $170M of Alpine Immune Sciences Inc stock for Q2 2022, down 24% quarter-over-quarter.
- 9 funds opened new Alpine Immune Sciences Inc positions in Q2 2022 and 6 closed out, a net change of +3 holders.
- The largest Alpine Immune Sciences Inc buyer in Q2 2022 was Great Point Partners, an estimated $4.64M added.
- The largest Alpine Immune Sciences Inc seller in Q2 2022 was Frazier Life Sciences Management, an estimated $10.3M sold.
Based on aggregated 13F filings for Q2 2022.